Lilly’s Taltz could achieve blockbuster status in plaque psoriasis market


(Photo Courtesy:

Eli Lilly's drug Taltz (ixekizumab), which was recently approved by the FDA for the treatment of adults with moderate-to-severe plaque psoriasis, is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its high clinical efficacy and good safety profile, according to an analyst with research and consulting firm GlobalData.

As explored in GlobalData's recent report on the psoriasis market, the last six years have seen an influx of novel plaque psoriasis treatments outside mainstay anti-tumor necrosis factor (anti-TNF) therapies. Indeed, Novartis' Cosentyx, the first-to market interleukin-17A (IL-17A) inhibitor launched in 2015, has shown superior efficacy over other approved biologics, most notably the anti-TNF therapy Enbrel.

Ms Alexandra Annis, GlobalData's Analyst covering Immunology, states: "Taltz has a shared mechanism of action with Cosentyx, and GlobalData anticipates it could be used ahead of a TNF inhibitor in biologic- and/or TNF-naïve patients in the psoriasis space. Although it will be competing with Cosentyx, which has a significant first-to-market advantage, Taltz offers more convenient dosing.

"The recommended dosing for Taltz is an initial 160 milligrams (mg) subcutaneous (SC) injection followed by an 80mg SC injection once every two weeks for 12 weeks, then 80mg every four weeks. In comparison, 300mg of SC Cosentyx is administered once a week, followed by 300mg every four weeks. In this way, Taltz will hold an edge in the anti-IL-17A market for psoriasis."

In terms of competition GlobalData believes Taltz may face within the anti-IL17 class, Valeant's brodalumab may pose a threat, which is in pre-registration in the US and Europe for plaque psoriasis.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email